LGND

Business Context and Reporting Period

Company: Ligand Pharmaceuticals Incorporated
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Ligand is an early-stage biotechnology company focused on discovering and developing drugs for thrombocytopenia, anemia, cancer, hormone-related diseases, osteoporosis, and inflammatory diseases. The company's strategy relies on internal research and development followed by licensing drug candidates to pharmaceutical partners for commercialization. In 2006 and 2007, Ligand divested its commercial product lines (Oncology and AVINZA), transitioning to a royalty-driven business model.

Key Financial Metrics

Note: 2007 Net Income is driven primarily by a $310.1 million pre-tax gain on the sale of the AVINZA product line and a $18.0 million gain on the sale of the Oncology product line, classified as discontinued operations.

Material Changes vs. Prior Period

• Revenue Composition: Revenue shifted from collaborative research and development fees to royalty income. In 2007, Ligand recognized $11.4 million in AVINZA royalties, whereas 2006 had no royalty revenue. Collaborative revenue decreased to $1.5 million in 2007 from $4.0 million in 2006 due to the completion of research phases with partners like TAP.
• Asset Sales: The company completed the sale of its AVINZA product line to King Pharmaceuticals in February 2007, resulting in net cash proceeds of approximately $289.4 million. The Oncology product line was sold to Eisai in October 2006.
• Capital Return: In April 2007, Ligand paid a special cash dividend of $2.50 per share, totaling $252.7 million, funded by proceeds from asset sales.
• Stock Repurchases: The company repurchased 6.2 million shares of common stock in 2007 for $39.6 million under a $100 million authorization.
• Investment Impairment: Ligand recorded a $1.3 million impairment loss on a $5.0 million commercial paper investment in Golden Key Ltd., which defaulted in October 2007.

Guidance, Outlook, Risks, and Contingencies

Outlook and Pipeline

• Eltrombopag (PROMACTA): Partnered with GlaxoSmithKline (GSK). An NDA for short-term treatment of ITP was submitted in December 2007 and granted priority review by the FDA in March 2008. Ligand expects royalties ranging from 5% to 10% based on sales thresholds.
• Bazedoxifene (Viviant): Partnered with Wyeth. NDAs for osteoporosis prevention and treatment are pending. An advisory committee meeting was expected in July 2008.
• Lasofoxifene: Partnered with Pfizer. An NDA for osteoporosis treatment was submitted in December 2007.
• Liquidity: Management believes cash, cash equivalents, and future royalty revenues will satisfy operating requirements for at least the next twelve months.

Risks and Contingencies

• SEC Investigation: An ongoing SEC investigation into the restatement of financial statements for 2002-2004 continues to divert management attention and incur legal costs.
• Intellectual Property Litigation:
  • Rockefeller University: Claims 25% of milestone and royalty payments related to eltrombopag. Ligand filed a declaratory judgment action in March 2008 to contest these claims.
  • Salk Institute: Seeking arbitration for at least $22 million related to Targretin royalties from the Eisai sale. Ligand disputes the validity of these claims.
• AVINZA Royalty Dependency: Future revenue is heavily dependent on AVINZA royalties from King Pharmaceuticals. Risks include generic competition (Actavis filed a Paragraph IV certification), patent challenges, and potential product safety issues.
• Indemnification Obligations: Ligand retains liability for product returns and certain indemnification claims related to the sold product lines (AVINZA and Oncology), with reserves totaling approximately $17.3 million for rebates and returns as of year-end.

Investor Verification Checklist

• AVINZA Royalty Sustainability: Verify the impact of the Actavis generic challenge on future AVINZA sales and royalty streams.
• Regulatory Approvals: Monitor FDA decisions on the NDA for eltrombopag (PROMACTA) and bazedoxifene, as these are critical for future milestone and royalty revenue.
• Legal Resolutions: Track the outcomes of the litigation with Rockefeller University and the arbitration with Salk Institute, as adverse rulings could result in significant cash outflows.
• SEC Investigation Status: Monitor for any updates regarding the SEC investigation into historical financial restatements.
• Investment Recovery: Assess the recovery potential of the defaulted Golden Key Ltd. commercial paper investment.